Mindpeak, a leader in AI-powered pathological solutions, announced it has raised $15.3 million in a Series A funding round. This funding round was led by ZEISS Ventures and InnoVentureFund, with participation from AI.FUND, the European Innovation Council Fund, etc. Even though Mindpeak has a cash-flow-positive core business, this new investment will enable the company to further expand the commercialization of its pioneering technologies across several geographies.
Mindpeak’s AI algorithms were among the first to be deployed for routine clinical diagnostics in both the US and EU. The company’s innovative solutions enable automated histological and immunohistochemical tissue analysis, helping experts make more confident decisions. To date, over 30,000 patient diagnoses have been supported using the AI solution. Biopharmaceutical companies also use this AI technology to predict the effectiveness of certain medications in cancer therapy and to enable targeted treatments.
Recently, Mindpeak expanded its product portfolio to include additional organs, biomarkers, and stainings. Strategic partnerships with leading healthcare organizations, such as Roche, along with positive regulatory developments, further bolster the company’s position in the market.
KEY QUOTES:
“With this new capital, we will accelerate the development and deployment of our AI solutions, empowering pathologists and researchers with faster, more accurate diagnostic tools. Our goal is to revolutionize cancer diagnostics and ultimately improve patient outcomes.”
- Felix Faber, CEO of Mindpeak
“Since its founding in 2018, Mindpeak has developed cutting-edge solutions, establishing itself as a prominent leader in the digital pathology market. Both as an investor and as a market partner, we are firmly convinced of Mindpeak’s promising future.”
- Mike Gänßler, Investment Manager at ZEISS Ventures
“Mindpeak’s commitment to innovation in digital pathology has been evident through their rapid product development and growing adoption across markets. This funding round will further solidify their position as a key player in the transformation of cancer diagnostics.”
- Gencer Sahin, Head of Investments at IFB Innovationsstarter GmbH / InnoVentureFund
